Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion.
BACKGROUND
Hyperthermic isolated limb perfusion (HILP) with melphalan as treatment for locally recurrent or in-transit malignant melanoma is frequently performed but the principle for calculating drug dosage remains poorly understood.


METHODS
This study examined the pharmacokinetic profile of 14 consecutive patients to determine what variables were associated with toxicity and tumor responses.


RESULTS
Marked fourfold variability was noted in patient plasma melphalan concentrations. We defined a factor--the ratio of estimated limb volume (Vesti) to melphalan volume of distribution (Vss), Vesti/Vss--that was much more strongly correlated with acute regional toxicity than either area under concentration-time curve or peak plasma concentration. In addition, we found that AUX2 was the best correlate of tumor response.


CONCLUSIONS
Pharmacokinetic evaluation of prospective HILP trials is critical to not only understand response and toxicity outcomes but also to potentially improve the therapeutic index of regional perfusion.
Cheng
Tsung-Yen
TY
Department of Surgery, Box 3118, Duke University Medical Center, Durham, NC 27710, USA.
Grubbs
Elizabeth
E
Abdul-Wahab
Omar
O
Leu
Szu-Yun
SY
Hung
Chen-Fang
CF
Petros
William
W
Aloia
Thomas
T
Fedrau
Randy
R
Pruitt
Scott
S
Colvin
Michael
M
Friedman
Henry
H
Tyler
Douglas
D
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D005121:Extremities; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008558:Melphalan / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy*
D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan